MAY 2 8 2003

1646

CASE PH-7148 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

James Epperson

Type or print name

Signatura June

May 23, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1646

Scott E. Priestley

APPLICATION NO: 10/039,317

RECEIVED

FILED: October 28, 2001

MAY 2 9 2003

FOR: Peptide Inhibitors of Hepatitis C Virus NS3 Protein

TECH CENTER 1600/2900

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

CASE PH-7148 NP

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 203-677-6974

Date:

James Epperson Agent for Applicants

Reg. No. 52,867

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

OIP (Use several sheets if necessary)

ATTY. DOCKET NO. PH-7148 NP APPLICATION NO. 10/039,317 APPLICANT Scott E. Priestley FILING DATE October 28, 2001

Group 1646

MAY 2 8 2003

U	S.	PA	TEN	TV	DOC	LU	ИEI	STV

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA			· · ·			
	AB				P	ECEI	VED
	AC						
	AD					MAY 2 9	2003
	AE				TECH	CENTER 1	600/2000
	AF				IEUN	DENIER I	000/2900
	AG						
	АН				,	 	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
Al	WO 98/17679	4/30/98	PCT Patent Application				
AJ	WO 98/22496	5/28/98	PCT Patent Application				
AK	WO 99/07734	2/18/99	PCT Patent Application				
AL	WO 99/07733	2/18/99	PCT Patent Application				
AM	WO 99/50230	10/7/99	PCT Patent Application				
AN	WO 00/09543	2/24/00	PCT Patent Application				
 AO	WO 00/09558	2/24/00	PCT Patent Application				
AP	WO 98/46630	10/22/98	PCT Patent Application				
AQ	WO 97/43310	11/20/97	PCT Patent Application				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

CVALUED	
АТ	E. Pizzi, et al, "Molecular Model of the Specificity Pocket of the Hepatitis C Virus Protease: Implications for Substrate Recognition," PROC. NATL. ACAD. SCI. USA, 91 , pp. 888-892, 1994
AS	P. Ingallinella, et al, "Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products," BIOCHEMISTRY, 37 , pp. 8906-8914, 1998
AR	C. Steinkuhler, et al, "Product Inhibition of the Hepatitis C Virus NS3 Protease," BIOCHEMISTRY, 37 , pp. 8899-8905, 1998

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

OIP (Use several sheets if necessary)

ATTY. DOCKET NO. PH-7148 NP APPLICATION NO. 10/039,317 APPLICANT Scott E. Priestley
FILING DATE October 28, 2001

Group 1646

MAY 2 8 2003

	j.	OTHER DOCUMENTS (Inclu	ding Author, Title, Date, Pertinent pages, Etc.)
Cherry Con	AU	A. Urbani, et al, "Substrate Specificity of BIOLOGICAL CHEMISTRY, 272 (1	of the Hepatitis C Virus Serine Protease NS3," THE JOURNAL 4), pp. 9204-9209, 1997
	AV	R. B. Perni, "NS3•4A Protease as a Ta NEWS PERSPECT, 13 (2), pp. 69-77,	arget for Interfering with Hepatitis C Virus Replication," DRUG 2000
	AW		RECEIVED
	AX		MAY 2 9 2003
	AY		TECH CENTER 1600/290
	AZ		
	ВА		
	ВВ		
	вс		
	BD		
	BE		
	BF		
	BG		·
	вн		
EXAMIN	ER		DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.